My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 94

    1.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.

    DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group.

    Diabetes Care. 2008 Dec;31(12):2315-7. Epub 2008 Sep 22.PMID: 18809631 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

    Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group.

    Diabetes Obes Metab. 2009 Feb;11(2):167-76.PMID: 19125778 [PubMed - indexed for MEDLINE]Related articles

    3.

    Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

    Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.

    Clin Ther. 2008 Mar;30(3):499-512.PMID: 18405788 [PubMed - indexed for MEDLINE]Related articles

    4.

    Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.

    Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group.

    Int J Clin Pract. 2009 Jan;63(1):46-55.PMID: 19125992 [PubMed - indexed for MEDLINE]Related articles

    5.

    Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

    Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

    Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.PMID: 17559733 [PubMed - indexed for MEDLINE]Related articles

    6.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    7.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

    Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

    8.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

    Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group.

    Curr Med Res Opin. 2009 Oct;25(10):2361-71.PMID: 19650752 [PubMed - in process]Related articles

    9.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    10.

    Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.

    Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.

    Clin Ther. 2008 Mar;30(3):513-27.PMID: 18405789 [PubMed - indexed for MEDLINE]Related articles

    11.

    Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.

    Rosenstock J, Sankoh S, List JF.

    Diabetes Obes Metab. 2008 May;10(5):376-86. Epub 2008 Mar 18.PMID: 18355324 [PubMed - indexed for MEDLINE]Related articles

    12.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

    Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

    Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713. PMID: 17485570 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.

    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.

    Br J Pharmacol. 2009 Jun;157(3):415-26. Epub 2009 Apr 3.PMID: 19371350 [PubMed - indexed for MEDLINE]Related articles

    16.

    Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

    Pratley RE.

    Expert Opin Pharmacother. 2009 Feb;10(3):503-12. Review.PMID: 19191685 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

    Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ.

    Diabetes Care. 2007 Apr;30(4):890-5. Epub 2007 Feb 2.PMID: 17277036 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Luis Bautista J, Bugos C, Dirnberger G, Atherton T.

    Clin Ther. 2003 Jan;25(1):194-209.PMID: 12637120 [PubMed - indexed for MEDLINE]Related articles

    19.

    Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

    Deacon CF.

    Curr Opin Investig Drugs. 2008 Apr;9(4):402-13. Review.PMID: 18393107 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group.

    Diabetes Care. 2006 Dec;29(12):2632-7.PMID: 17130196 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity